Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
14.55+0.90 (+6.59%)
At close: 04:00PM EST
14.85 +0.30 (+2.06%)
After hours: 07:02PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close13.65
Open13.98
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range13.91 - 14.88
52 Week Range10.61 - 47.71
Volume901,628
Avg. Volume1,024,276
Market Cap725.873M
Beta (5Y Monthly)0.89
PE Ratio (TTM)17.74
EPS (TTM)0.82
Earnings DateApr 26, 2023 - May 01, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
175% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EBS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Emergent Biosolutions, Inc.
    EBS: Raising target price to $11.00EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • Reuters

    UPDATE 1-FDA identifies recall of Emergent's decontamination kits as most serious

    The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious type. Emergent had recalled kits with distribution dates between Oct. 4 and Oct. 14, 2022. The company's investigation showed that all kits, other than the recalled lots, met quality criteria and were suitable for use, Emergent said in a statement to Reuters.

  • Reuters

    FDA identifies recall of Emergent's decontamination kits as most serious

    The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious type. The contract manufacturer began the recall of 3500 units of the kit in November, after receiving three customer complaints of leakage from the packets. Emergent said that so far no serious injuries or deaths related to the issue were reported.

  • Reuters

    U.S. FDA panel to review Emergent's OTC opioid overdose drug

    The U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc's over-the-counter (OTC) nasal spray to treat suspected opioid overdoses. Emergent is seeking the Food and Drug Administration's (FDA)approval for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country.

Advertisement
Advertisement